The debate surrounding cancer endpoints has focused on the issue of quality of life and progression. Panelists shared some of the challenges in assessing quality of life, since it can be a fickle and subjective process. The data can be hard to nail down since patients don’t always fill out the forms. The critical issues include survival rates, improved quality of life and progression of disease. Everything must be taken into consideration to determine endpoints, which is why the issue is hotly debated.
Subscribe to our e-newsletterVIEW OUR CURRENT ISSUE >
TagsFood BIOTECH Health Care health biotech industry Plant biotechnology Sustainability Industry Analysis GMOs BIO Investor Forum patent global food crisis BIO Events USPTO Intellectual Property healthcare BIO EVENT FDA biotechnology public policy
- Most Popular
Latest VideoJohn Chambers, Vice Chairman, Head of Healthcare Investment Banking, ROTH Capital Partners View All >